Analogy 1: Lexeo Therapeutics is like a clinical-stage BioMarin Pharmaceutical, but focused on gene therapies for genetic heart and Alzheimer's diseases.

Analogy 2: Lexeo Therapeutics is like Vertex Pharmaceuticals, but developing gene therapies for severe cardiovascular and neurological genetic diseases.

• LX2006: A gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy, currently in a Phase 1/2 clinical trial.
• LX2020: A gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy (ACM) caused by PKP2 gene mutations, expected to begin a Phase 1/2 clinical trial.
• LX1001: A gene therapy candidate for the treatment of APOE4 homozygous patients with Alzheimer’s disease, currently in a Phase 1/2 clinical trial.

Lexeo Therapeutics (LXEO) is a clinical-stage genetic medicine company. This means that its product candidates are currently in various phases of clinical trials and have not yet received regulatory approval for commercial sale. Consequently, Lexeo Therapeutics does not currently have any major customers or generate revenue from product sales.

If and when their investigational therapies are approved, their end-users would be patients suffering from specific diseases, such as Friedreich’s ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and APOE4-associated Alzheimer’s disease. Their commercial customers would likely be healthcare providers, hospitals, and potentially specialized pharmacies or healthcare systems, depending on the final distribution model.

R. Nolan Townsend, Chief Executive Officer

R. Nolan Townsend has served as Chief Executive Officer and a member of the Board of Directors of Lexeo Therapeutics since January 2020. Prior to joining Lexeo, Mr. Townsend held senior leadership roles at Pfizer, including President of Pfizer Rare Disease for the North America region and President of Pfizer Rare Disease for the International markets. His tenure at Pfizer spanned over a decade, with responsibilities across Corporate Finance, Corporate Strategy, Operations, Marketing, General Management, and Commercial leadership in various global regions. Earlier in his career, he worked in the healthcare investment banking group at Lehman Brothers, advising healthcare companies on strategic financing transactions and mergers and acquisitions. Mr. Townsend currently serves on the Board of Directors of Arbor Biotechnologies, the Biotechnology Innovation Organization (BIO), and the Martha's Vineyard Museum, and is an appointee to the New York City Economic Development Corporation's Life Sciences Advisory Council. He holds an MBA from Harvard Business School and a Bachelor of Arts in Economics from the University of Pennsylvania.

Louis Tamayo, Chief Financial Officer

Louis Tamayo was appointed Chief Financial Officer of Lexeo Therapeutics, effective August 15, 2025. Before joining Lexeo, Mr. Tamayo held various senior leadership roles at Siemens Healthineers, including Senior Vice President of Operational Excellence from February 2023 to September 2024, Senior Vice President and Head of Product Franchise Finance from October 2020 to February 2023, and Vice President and Head of R&D Finance from 2016 to October 2020. From 2014 to 2016, he served as Vice President and Business Unit CFO for the global Diabetes Care business at Becton, Dickinson & Company. Mr. Tamayo also spent a significant portion of his career at Pfizer from 2000 to 2014, where his roles included Senior Director – Regional Head of Strategy & Analytics, Regional Finance Director – US Primary Care, and Director – Asia-Pacific Finance Program Office. He earned a B.B.A. in Finance and Marketing from Northeastern University.

Narinder Bhalla, MD, Chief Medical Officer

Dr. Narinder Bhalla was appointed Chief Medical Officer of Lexeo Therapeutics effective January 20, 2026. He brings over two decades of experience as an interventional cardiologist and nearly a decade in biopharma leadership. Dr. Bhalla previously held senior roles at AstraZeneca and, most recently, served as Senior Vice President and Head of Global Medical, Immunology & Cardiovascular at Bristol Myers Squibb. He is recognized for his expertise in building and scaling high-impact medical and clinical development organizations and leading successful global product launches.

José Manuel Otero, PhD, Chief Operating Officer

Dr. José Manuel Otero was appointed Chief Operating Officer of Lexeo Therapeutics, effective January 2, 2026, transitioning from his previous role as Chief Technical Officer. Under his leadership, Lexeo has achieved industry-leading cost of goods, successfully executed a major manufacturing platform transition under high regulatory standards, and consistently delivered timely clinical supply across its programs.

Gregory Aubert, MD, PhD, Vice President, Clinical Development, Early Stage Cardiology

Dr. Gregory Aubert is a cardiologist and physician-scientist with a specialization in cardiovascular genetics, gene therapy, and cardiometabolic research. He previously served as the Director of the Clinical and Translational Research Division at the Loyola University Cardiovascular Research Institute, where he led preclinical, early-stage, and clinical research programs focused on cardiometabolism and inherited cardiovascular diseases. During his time at Loyola, Dr. Aubert also founded the institution's Cardiovascular Genetics Clinic.

Key Risks to the Business

1. High Risk of Clinical Trial Failure and Inability to Obtain Regulatory Approval: Lexeo Therapeutics is a clinical-stage genetic medicine company with all its product candidates (LX2006, LX2020, and LX1001) currently in early-stage Phase 1/2 clinical trials. The success of the company is fundamentally reliant on these candidates successfully demonstrating safety and efficacy through further clinical development and ultimately securing regulatory approvals from bodies such as the U.S. Food and Drug Administration (FDA). Clinical development is an inherently lengthy, expensive, and uncertain process with a high rate of failure, and any setbacks or failures in these trials would significantly jeopardize the company's ability to commercialize its products.
2. Challenges and Uncertainties Specific to Gene Therapy Development: The company's focus on gene therapy introduces unique and complex risks. These include potential safety concerns such as off-target effects, immunogenicity, and the long-term durability and safety profiles of gene-edited cells. Additionally, there are significant challenges related to the manufacturing complexity and scalability of gene therapy products, as well as an evolving regulatory landscape for these novel treatments, all of which can impact the successful development and commercialization of Lexeo's pipeline.

Lexeo Therapeutics (LXEO) is a clinical-stage genetic medicine company developing therapies for various devastating diseases. The addressable markets for its main product candidates are as follows:

LX2006 for Friedreich’s ataxia cardiomyopathy

The addressable market for Friedreich's ataxia, which includes cardiomyopathy, across the 7 major markets (United States, Germany, France, Italy, Spain, United Kingdom, and Japan) was valued at approximately USD 660.4 million in 2024. This market is projected to grow to USD 1,825.0 million by 2035, exhibiting a compound annual growth rate (CAGR) of 9.65% from 2025 to 2035.

LX2020 for Arrhythmogenic Cardiomyopathy (PKP2-ACM)

The addressable market size in monetary terms for Arrhythmogenic Cardiomyopathy (PKP2-ACM) is currently not available in the provided information. However, PKP2-ACM affects approximately 50,000 people in the U.S. and EU.

LX1001 for APOE4 homozygous Alzheimer’s disease

The addressable market for Alzheimer's disease in the 7 major markets (United States, Germany, France, Italy, Spain, United Kingdom, and Japan) was approximately USD 5,048 million in 2025. This market is projected to reach USD 34,335 million by 2034, growing at a CAGR of 23.7%.

Lexeo Therapeutics (LXEO) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily stemming from the progression of its clinical-stage genetic medicine pipeline:

1. Advancement and Potential Commercialization of LX2006 for Friedreich’s Ataxia Cardiomyopathy: As Lexeo’s most advanced cardiovascular product candidate, successful progression of LX2006 through its ongoing Phase 1/2 clinical trial, particularly with the expected additional interim data in mid-2024, is crucial. Positive results and subsequent movement towards later-stage trials and eventual market approval would unlock a significant new revenue stream by addressing a high unmet need in Friedreich’s ataxia cardiomyopathy.
2. Advancement and Potential Commercialization of LX1001 for APOE4-Associated Alzheimer’s Disease: LX1001 targets APOE4 homozygous patients with Alzheimer’s disease, a substantial market with a high unmet need. With enrollment in the Phase 1/2 trial expected to complete by the end of 2023 and additional interim data from all cohorts anticipated in the second half of 2024, successful clinical development and eventual market entry represent a major driver of future revenue growth for the company.
3. Initiation and Early Clinical Readouts for LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy (PKP2-ACM): The second most advanced cardiovascular candidate, LX2020, received IND clearance in July 2023. The planned dosing of the first patient in a Phase 1/2 clinical trial in the first half of 2024, followed by an interim data readout from cohort 1 in the second half of 2024, marks critical steps in its development pathway. Successful early clinical data will lay the groundwork for this program to contribute to future revenue growth by addressing PKP2-ACM.

Share Issuance

• Lexeo Therapeutics completed an initial public offering (IPO) on November 3, 2023, raising approximately $100 million by offering 9,090,910 common stock shares at $11 per share.
• In October 2025, the company closed an underwritten public offering and a concurrent private placement, resulting in total gross proceeds of approximately $153.8 million. This included the sale of 17,968,750 shares in the public offering and pre-funded warrants for 1,250,015 shares in the private placement.
• In May 2025, Lexeo Therapeutics arranged a private placement that generated approximately $80 million through the issuance and sale of over 20 million shares of common stock and pre-funded warrants.

Inbound Investments

• Lexeo Therapeutics has raised a total of $185 million across 10 funding rounds, which include early-stage, post-IPO, and grant rounds.
• The company closed an oversubscribed equity financing round in March 2024, raising approximately $95 million, co-led by Braidwell LP and Adage Capital.
• Significant institutional investors supporting Lexeo Therapeutics include Janus Henderson, Balyasny Asset Management L.P., RA Capital Management L.P., and Frazier Life Sciences.

Capital Expenditures

• Over the last 12 months, Lexeo Therapeutics reported capital expenditures of approximately -$397,000.
• In Q3 2025, the company invested $289,000 in capital expenditures, primarily for funding long-term assets and infrastructure.
• The company generally maintains very low capital spending, with its cash needs predominantly allocated to operational activities.